These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17062331)

  • 1. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
    Drinka PJ
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
    Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W
    Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
    Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
    Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study].
    Kalchthaler M; Mühlich S; Rothe P
    MMW Fortschr Med; 2011 Jan; 152 Suppl 4():119-24. PubMed ID: 21598462
    [No Abstract]   [Full Text] [Related]  

  • 5. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
    Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S
    Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin: scientific evidence in the treatment of overactive bladder.
    Santos JC; Telo ER
    Arch Esp Urol; 2010 Apr; 63(3):197-213. PubMed ID: 20431184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary.
    Yokoyama O; Yamaguchi O; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; Yamada S
    J Urol; 2011 Jul; 186(1):170-4. PubMed ID: 21575976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
    Tanaka Y; Masumori N; Tsukamoto T
    Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Schaefer W
    BJU Int; 2009 Feb; 103(4):554-5. PubMed ID: 19187349
    [No Abstract]   [Full Text] [Related]  

  • 16. [Urinary urgency].
    MMW Fortschr Med; 2008 Jul; 150(28-31):58-9. PubMed ID: 19009709
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
    Millard RJ; Halaska M
    Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solifenacin succinate (VESIcare): overactive bladder therapy.
    Kosier JH; Combest W; Newton M
    Urol Nurs; 2006 Dec; 26(6):496-7. PubMed ID: 17253085
    [No Abstract]   [Full Text] [Related]  

  • 20. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.